Klafki, Hans-Wolfgang

[["dc.bibliographiccitation.artnumber","94"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Alzheimer's Research & Therapy"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Aichholzer, Freyja"],["dc.contributor.author","Klafki, Hans-Wolfgang"],["dc.contributor.author","Ogorek, Isabella"],["dc.contributor.author","Vogelgsang, Jonathan"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Scherbaum, Norbert"],["dc.contributor.author","Weggen, Sascha"],["dc.contributor.author","Wirths, Oliver"],["dc.date.accessioned","2021-11-25T11:07:12Z"],["dc.date.accessioned","2022-08-18T12:39:08Z"],["dc.date.available","2021-11-25T11:07:12Z"],["dc.date.available","2022-08-18T12:39:08Z"],["dc.date.issued","2021-05-04"],["dc.date.updated","2022-07-29T12:17:48Z"],["dc.description.abstract","Abstract\r\n \r\n Background\r\n Alzheimer’s disease (AD) is a neurodegenerative disorder associated with extracellular amyloid-β peptide deposition and progressive neuron loss. Strong evidence supports that neuroinflammatory changes such as the activation of astrocytes and microglia cells are important in the disease process. Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a transmembrane glycoprotein that has recently been associated with an emerging role in neuroinflammation, which has been reported to be increased in post-mortem brain samples from AD and Parkinson’s disease patients.\r\n \r\n \r\n Methods\r\n The present study describes the partial “fit for purpose” validation of a commercially available immunoassay for the determination of GPNMB levels in the cerebrospinal fluid (CSF). We further assessed the applicability of GPNMB as a potential biomarker for AD in two different cohorts that were defined by biomarker-supported clinical diagnosis or by neuroimaging with amyloid positron emission tomography, respectively.\r\n \r\n \r\n Results\r\n The results indicated that CSF GPNMB levels could not distinguish between AD or controls with other neurological diseases but correlated with other parameters such as aging and CSF pTau levels.\r\n \r\n \r\n Conclusions\r\n The findings of this study do not support GPNMB in CSF as a valuable neurochemical diagnostic biomarker of AD but warrant further studies employing healthy control individuals."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.citation","Alzheimer's Research & Therapy. 2021 May 04;13(1):94"],["dc.identifier.doi","10.1186/s13195-021-00828-1"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/93530"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112967"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.publisher","BioMed Central"],["dc.relation.eissn","1758-9193"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.subject","Alzheimer’s disease"],["dc.subject","GPNMB"],["dc.subject","Cerebrospinal fluid"],["dc.subject","Biomarker"],["dc.subject","Inflammation"],["dc.subject","Immunoassay"],["dc.title","Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","108"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Acta Neuropathologica Communications"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Hüttenrauch, Melanie"],["dc.contributor.author","Ogorek, Isabella"],["dc.contributor.author","Klafki, Hans"],["dc.contributor.author","Otto, Markus"],["dc.contributor.author","Stadelmann, Christine"],["dc.contributor.author","Weggen, Sascha"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Wirths, Oliver"],["dc.date.accessioned","2019-07-09T11:46:01Z"],["dc.date.available","2019-07-09T11:46:01Z"],["dc.date.issued","2018"],["dc.description.abstract","Abstract Alzheimer’s disease (AD) is an irreversible, devastating neurodegenerative brain disorder characterized by the loss of neurons and subsequent cognitive decline. Despite considerable progress in the understanding of the pathophysiology of AD, the precise molecular mechanisms that cause the disease remain elusive. By now, there is ample evidence that activated microglia have a critical role in the initiation and progression of AD. The present study describes the identification of Glycoprotein nonmetastatic melanoma protein B (GPNMB) as a novel AD-related factor in both transgenic mice and sporadic AD patients by expression profiling, immunohistochemistry and ELISA measurements. We show that GPNMB levels increase in an age-dependent manner in transgenic AD models showing profound cerebral neuron loss and demonstrate that GPNMB co-localizes with a distinct population of IBA1-positive microglia cells that cluster around amyloid plaques. Our data further indicate that GPNMB is part of a microglia activation state that is only present under neurodegenerative conditions and that is characterized by the up-regulation of a subset of genes including TREM2, APOE and CST7. In agreement, we provide in vitro evidence that soluble Aβ has a direct effect on GPNMB expression in an immortalized microglia cell line. Importantly, we show for the first time that GPNMB is elevated in brain samples and cerebrospinal fluid (CSF) of sporadic AD patients when compared to non-demented controls. The current findings indicate that GPNMB represents a novel disease-associated marker that appears to play a role in the neuroinflammatory response of AD."],["dc.identifier.doi","10.1186/s40478-018-0612-3"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15381"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59366"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.intern","In goescholar not merged with http://resolver.sub.uni-goettingen.de/purl?gs-1/15408 but duplicate"],["dc.publisher","BioMed Central"],["dc.rights","CC BY 3.0"],["dc.rights.holder","The Author(s)."],["dc.rights.uri","https://creativecommons.org/licenses/by/3.0"],["dc.title","Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]